Mass. Senate proposes ban on all pharma gifts

Share this article:
The leader of the Massachusetts State Senate has proposed legislation banning all gifts to doctors from pharmaceutical companies. If enacted, the move would make the state the first in the country to ban gifts outright.

“There's going to be a climate change, and there has to be a climate change; otherwise our healthcare reform will implode, just under the costs,” said Massachusetts State Senate president Therese Murray in published reports.

Murray's measure is part of a set of healthcare reforms measures filed in a bill that also includes requiring all doctors statewide to adopt electronic medical records by 2015, allowing patients to choose nurse practitioners as primary care providers, and forcing public reviews of any insurance company efforts to boost annual premiums by more than 7%.

The ban forbids the pharmaceutical industry from giving -- and doctors, their families or employees from receiving -- gifts from drug companies. Gifts include payments, entertainment, meals, travel, honorariums, subscriptions, even a pen with a drug company logo.

The legislation would continue to permit distribution of drug samples to doctors for the exclusive use of their patients. Anyone who violates the ban could be fined $5,000, face two years imprisonment, or both, under the proposal.

Currently Minnesota and Vermont are the only states with mandatory physician gift reporting laws.
In Minnesota, legislators enacted a ban on gifts in excess of $50 from pharmaceutical companies. In Vermont, legislators have passed laws requiring pharmaceutical company representatives to disclose the dollar value of gifts over $25 to doctors.

Julie Corcoran, deputy vice president of PhRMA, told The Boston Globe that the industry's sales people are "highly educated and trained by their companies." The group opposes any ban, saying the pharmaceutical industry is already heavily regulated by the FDA. "I'm not aware of any kind of evidence or studies that link promotional or marketing materials with the cost of healthcare," she said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...